Cairo University
Cairo, Cairo Governorate, 6890, Egypt
Location status: Recruiting
NCT Number: NCT07022704
Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial
Interested in participating?
Request Info20 year–65 year
All sexes
Observational
Cairo, Cairo Governorate, 6890, Egypt
Location status: Recruiting
doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
Time frame: before and 10 minutes after doxappram
Time frame: before and 10 minutes after doxapram
Time frame: before and 10 minutes after doxapram
Contact information is provided by the study sponsor or research team.
Cairo University
Other
The Influence of Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial: a Prospective Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07404826
COPD, Chronic Disease
Cincinnati, Ohio, United States
View Trial DetailsNCT06935825
COPD, Chronic Disease
Amsterdam, Netherlands
View Trial DetailsNCT07566195
COPD, Chronic Disease
Aix-en-Provence, France
View Trial DetailsNCT07567872
COPD, Chronic Disease
Chengdu, Sichuan, China
View Trial Details